ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors

Grant

Date/time Interval

  • June 28, 2017 - June 27, 2018
  • Total Award Amount

  • 0.00
  • Direct Costs

  • 0.00
  • Sponsor Award Id

  • Contributor

  • Alva, Elizabeth   Investigator  
  • Friedman, Gregory   Investigator  
  • Galtarossa Xavier, Ana   Investigator  
  • Whelan, Kimberly   Investigator